Survival After Resection of Gastrointestinal @entity5 and Sarcoma Liver Metastases in 146 XXXX .

@entity1 @entity242 @entity5 @entity1822 @entity674 @entity2213
BACKGROUND: We investigated outcomes by @entity5 type in @entity1 who underwent resection of liver metastases from @entity674 ( @entity674 ), @entity1822 , and other @entity242 . METHOD: Our institutional liver database was used to identify @entity1 who underwent resection from 1998 through 2013. Histopathological, clinical, and survival data were analyzed. RESULTS: One hundred forty-six @entity1 underwent resection of liver metastases from @entity674 (n   =   49), @entity1822 (n   =   47), or other @entity242 (n   =   50). The 5-year overall survival (OS) rates in @entity1 with @entity674 , @entity1822 , and other @entity242 were 55.3, 48.4, and 44.9  %, respectively, and the 10-year OS rates were 52.5, 9.2, and 23.0  %, respectively. The 5-year recurrence-free survival (RFS) rate was better for @entity674 (35.7  %; p   =   0.003) than for @entity1822 (3.4  %) and other @entity242 (21.4  %). Lung recurrence was more common for @entity1822 (36  % of @entity1 ; p   <   0.0001) than for other @entity242 (12  %) and @entity674 (2  %). For @entity674 , the findings support a benefit of @entity2213 regarding the 5-year RFS rate compared to resection alone (47.1 vs. 9.5  %; p   =   0.013). For @entity1822 , @entity5 location did not affect the 5-year RFS rate (intraabdominal 14.5  %; other location 0  %; p   =   0.182). CONCLUSION: Liver metastases from @entity674 , @entity1822 , and other @entity242 should be assessed separately as their survival and recurrence patterns are different. This is especially important for @entity674 , for which @entity2213 is now available.
